Efficacy and Safety of Remimazolam for Procedural Sedation: A Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis
Background: Remimazolam is a new ultrashort-acting benzodiazepine. Remimazolam has been approved for procedural sedation by the US Food and Drug Administration in 2020. However, prior trials and the participants they enrolled were limited.Aim: In this meta-analysis, we investigated the effectiveness...
Main Authors: | Bo-Jyun Jhuang, Bo-Han Yeh, Yen-Ta Huang, Pei-Chun Lai |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.641866/full |
Similar Items
-
Efficacy and Safety of Remimazolam in Endoscopic Sedation—A Systematic Review and Meta-Analysis
by: Xianlin Zhu, et al.
Published: (2021-07-01) -
Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent
by: Gavin J. Kilpatrick
Published: (2021-07-01) -
Remimazolam: The future of its sedative potential
by: Basavana Gouda Goudra, et al.
Published: (2014-01-01) -
Oliceridine and its potential to revolutionize GI endoscopy sedation
by: Basavana Goudra, et al.
Published: (2020-01-01) -
Anesthetic management for a patient with myotonic dystrophy with remimazolam
by: Yasuhiro Morimoto, et al.
Published: (2021-01-01)